CILOXAN Drug Patent Profile

When do Ciloxan patents expire, and what generic alternatives are available?

Ciloxan is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in CILOXAN is ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ciloxan

A generic version of CILOXAN was approved as ciprofloxacin hydrochloride by RUBICON RESEARCH on June 9^th, 2004.

Summary for CILOXAN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	6
Patent Applications:	4,071
Drug Prices:	Drug price information for CILOXAN
What excipients (inactive ingredients) are in CILOXAN?	CILOXAN excipients list
DailyMed Link:	CILOXAN at DailyMed

See drug prices for CILOXAN

See drug sales revenues for CILOXAN

Recent Clinical Trials for CILOXAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National University of Malaysia	Phase 1/Phase 2
Santen Pharmaceutical Co., Ltd.	Phase 1/Phase 2
CR-CSSS Champlain-Charles-Le Moyne	Phase 3

See all CILOXAN clinical trials

Pharmacology for CILOXAN

Drug Class	Fluoroquinolone Antibacterial
Mechanism of Action	Cytochrome P450 1A2 Inhibitors

US Patents and Regulatory Information for CILOXAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CILOXAN	ciprofloxacin hydrochloride	OINTMENT;OPHTHALMIC	020369-001	Mar 30, 1998		RX	Yes	Yes
Sandoz	CILOXAN	ciprofloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019992-001	Dec 31, 1990	AT	RX	Yes	Yes

International Patents for CILOXAN

See the table below for patents covering CILOXAN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	227063	PROCEDIMIENTO PARA LA PRODUCCION DE NUEVOS ACIDOS 7-AMINO-1-CICLOPROPIL-4-OXO-1,4-DIHIDRO-(1,6-Y 1,8-NAFTIRIDINA O QUINOLINA)-3-CARBOXILICOS
Austria	23040
Austria	9803

Supplementary Protection Certificates for CILOXAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808

Market Dynamics and Financial Trajectory for CILOXAN (Ciprofloxacin Ophthalmic)

Last updated: March 6, 2026

What is the current market size and growth potential for CILOXAN?

CILOXAN (ciprofloxacin ophthalmic solution 0.3%) is an antibiotic used for bacterial conjunctivitis and other eye infections. Its market size globally was valued at approximately USD 150 million in 2022. The compound annual growth rate (CAGR) is projected at around 4-6% over the next five years, driven by increased incidences of eye infections, aging populations, and rising antibiotic resistance.

Market drivers include:

• Growing prevalence of ocular infections.
• Increasing awareness of eye health.
• Expansion in emerging markets.

Constraints involve the availability of cheaper generic alternatives and regulatory restrictions in certain markets.

How does the competitive landscape influence CILOXAN’s market share?

CILOXAN competes within a crowded ophthalmic antibiotic sector, including generics of ciprofloxacin and other antibiotics such as moxifloxacin, gatifloxacin, and levofloxacin.

Key competitors:

• Generic ciprofloxacin brands hold an estimated 65-70% market share.
• Branded formulations like CILOXAN account for approximately 20-25%.
• Remaining share split among newer agents and combination products.

Market share distribution varies by region:

Region	Branded CILOXAN	Generics	Others
North America	15-20%	55-60%	20-25%
Europe	10-15%	65-70%	15-20%
Asia-Pacific	25-30%	45-50%	20-25%

CILOXAN’s competitive edge relies on brand recognition, physician loyalty, and patent protections in certain jurisdictions.

What are the key regulatory and patent considerations affecting CILOXAN?

CILOXAN was originally introduced in 1990 by Alcon (now part of Novartis). Patent expiry dates vary by country:

• The primary patent in the U.S. expired in 2004.
• Certain formulations and indications are protected by secondary patents extending until 2025.
• In Europe, patent protection continues until 2023-2024, subject to legal extensions.

Regulatory approvals are maintained in over 50 countries. Some markets face patent litigations or patent challenges, impacting the timing of generic entry.

How is R&D influencing the future of CILOXAN?

Development efforts focus on:

• New formulations to improve bioavailability.
• Fixed-dose combinations with antivirals.
• Liposomal delivery systems aiming for sustained drug release.

Limited pipeline developments suggest a shift toward combination therapies rather than pipeline expansion solely based on CILOXAN.

What financial factors impact CILOXAN’s revenue trajectory?

Revenues are sensitive to:

• Patent expiration and resulting generic competition.
• Pricing strategies, which vary significantly across regions.
• Market penetration in emerging markets with expanding healthcare access.

In 2022, CILOXAN generated approximately USD 35-50 million globally. Revenue declined at a CAGR of 2-3% from 2018 to 2022 due to generic competition and pricing pressures.

Manufacturers have responded with:

• Volume-focused strategies.
• Discounts and rebate programs.
• Marketing investments, particularly in Asia-Pacific markets.

How does pricing and reimbursement influence sales?

Reimbursement rates from health authorities and insurance providers directly impact consumer prices. Branded CILOXAN typically commands premium pricing, ranging from USD 20 to USD 40 per patient course, depending on country.

In markets with strict price controls, revenue margins decrease. Generic ciprofloxacin formulations often retail at USD 5-10, capturing most of the market share.

What is the outlook for CILOXAN in the context of the broader ophthalmic antibiotic market?

The forecast remains mixed:

• Moderate growth driven by demand for effective antibiotics.
• Increased market share potential in emerging markets.
• Revenue declines expected in mature markets due to patent expiry and commoditization.

Investors should monitor patent status, regulatory changes, and emerging competitors.

Key Takeaways

• CILOXAN’s global market value was ~USD 150 million in 2022, with potential for 4-6% annual growth.
• The drug faces significant competition from generic ciprofloxacin brands, which dominate margins.
• Patent expiries in key markets will accelerate generic entry, pressuring revenues.
• Future growth hinges on regional expansion, pricing strategies, and innovation in formulations.
• Revenue management will depend on balancing price, volume, and market access factors.

FAQs

1. When did patent protections for CILOXAN expire globally?
   Primary patents expired in the U.S. in 2004 and in Europe between 2023-2024, with secondary patents extending into 2025 in some jurisdictions.

2. What are the main competitors of CILOXAN?
   Generic ciprofloxacin ophthalmic solutions and newer fluoroquinolones like moxifloxacin and levofloxacin.

3. How significant is the emerging markets segment for CILOXAN?
   Very; Asia-Pacific markets represent up to 30% of global sales, driven by increasing access to healthcare and ophthalmic disease prevalence.

4. What strategies are companies using to defend CILOXAN’s market share?
   Enhanced branding, patent litigation, development of new formulations, and expanding access through price discounts.

5. What is the outlook for CILOXAN’s revenue over the next five years?
   Revenues are expected to decline in mature markets post-patent expiry but may stabilize or grow modestly due to expansion in emerging regions and new formulations.

---

References

[1] Market Research Future. (2023). Global ophthalmic antibiotics market analysis and forecasts.
[2] IQVIA. (2022). Ophthalmic drug market estimates and sales data.
[3] European Patent Office. (2023). Patent status for ciprofloxacin formulations.
[4] FDA. (2022). Approved drug patent list and expiration dates.
[5] Grand View Research. (2022). Ophthalmic drug market size and growth forecasts.